The impact of the Sentinel Node concept on the overall survival, disease-free survival and axillary recurrence of Breast Cancer patients
Abstract
Introduction and aims: The Sentinel Node (SN) concept emerged as a way to improve Breast Cancer (BC) staging and to reduce the morbidity of the Axillary Dissection (AD). But the influence of the SN concept on long term BC outcomes is not well defined. The aim of this work is to assess the impact of the SN concept on the overall and disease-free survival and on the axillary recurrence, in a prospectively controlled series of BC patients.
Methods: This revision includes 394 consecutive BC patients, from two successive randomized clinical protocols. The first (n=166) elapsed from April 2001 to June 2003 and the second (n=228) accrued from Septem- ber 2003 to January 2005. The first study included patients with tumours less than 30mm and the pN0sn patients were randomized between AD and SN only. The second study was divided into two groups. Group A received uT1 patients; pN0sn patients were spared from the AD and pN+sn patients were submitted to AD. Group B received uT2 patients; those with pN0sn were randomized between AD and SN only. Patients were followed-up at the out-patient breast clinic, every 3 months during the first 3 years, every 6 months until 5 five years and then yearly. Events were prospectively registered in an Institutional database.
Results: Median patient’s age was 55 years (range: 20-78). Median follow-up time was 66 months (range: 4-100). Two men were included. Mean overall survival time for SN only patients was 98 months and for the AD patients was 93 months (p=0.003). Mean relapse-free survival time for the SN only patients was 97 months and for the AD patients was 99 months (p-0.43). At five years of follow-up, overall survival was 98% for the SN only group and 92% for the AD group and disease-free survival was 99% for the SN only group and 100% for the AD group. There were not detected axillary nodal recurrences among SN only patients or between AD patients.
Conclusions: Long-term follow-up of BC patients submitted to SN biopsy-only showed similar results to AD submitted patients, in terms of overall survival, disease-free survival and axillary node recurrence, therefore ensuring clinical long-lasting adequacy of the SN concept.
Keywords: Breast Cancer, Sentinel Node, Long-term follow-up.
Downloads
References
Mansel RE, Fallowfield L, Kissin M et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in opera- ble breast cancer: the ALMANAC trial. J Natl Cancer Inst 2006; 98: 599-609.
Fougo JL, Dinis-Ribeiro M, Araújo C et al. Impacto de la linfadenectomía sobre la recurrencia axilar y la morbilidad del miembro superior en pacientes con cáncer de mama y ganglio centinela negativo. Estudio prospectivo aleatorizado. Cir Esp 2011; 89: 307-16.
Krag DN, Ashikaga T, Harlow SP, Weaver DL. Development of sentinel node targeting technique in breast cancer patients. Breast J 1998; 4: 67-74.
Veronesi U, Paganelli G, Galimberti V et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph- -nodes. Lancet 1997; 349: 1864-7.
Fougo JL O conceito de Gânglio Sentinela e o Cancro da Mama: validação de uma técnica de identificação do Gânglio Sentinela. Tese de Mestrado em Oncologia. Universidade do Porto. 2003.
Veronesi U, Paganelli G, Viale G, Galimberti V, Luini A et al. Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series. J Natl Cancer Inst 1999; 91: 368-73
Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S et al. A randomized comparison of sentinel node biopsy with routine axillary dissection in breast cancer. New Engl J Med 2003; 349: 546-53
Veronesi U, Galimberti V, Paganelli G, Maisonneuve P, Viale G et al. Axillary metastases in breast cancer patients with negative sentinel nodes. A follow-up of 3548 cases. Eur J Cancer 2009; 45: 1381-8
Fougo JL, Afonso M, Senra FS et al. Predictive factors for non-sentinel lymph node involvement in breast cancer patients with a positive node: should we consider sentinel node-related factors? Clin Trans Oncol 2009; 11: 165-71
Langer I, Guller U, Hsu-Schmitz S, Ladewig A, Viehl C et al. Sentinel lymph node biopsy is associated with improved survival compared to level I & II axillary lymph node dissection in node negative breast cancer patients. Eur J Surg Oncol 2009; 35: 805-13
Carlo J, Grant M, Knox S, Jones R, Hamilton C, Livingston S, Kuhn J. Survival analysis following sentinel lymph node biopsy: a validation trial demonstrating its accuracy in staging early breast cancer. BUMC Proceedings 2005; 18: 103-7
Kiluk J, Ly Q, Santillan A, Meade T, Ramos D et al. Axillary recurrence rate following negative sentinel node biopsy for invasive breast cancer: long-term follow-up. Ann Surg Oncol 2010; 17: 552-7
de Kanter A, Menke-Pluymers M, Wouters M, Burgmans I, van Geel A, Eggermont A. 5-year follow-up of sentinel node negative breast cancer patients. Eur J Surg Oncol 2006; 32: 282-6
Naik A, Fey J, Gemignani M, Heerdt A, Montgomery L et al. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection. A follow-up study of 4008 procedures. Ann Surg 2004; 240: 462-71.
Cody HS 3rd, UrbanJA. Internal mammary node status: a major prognosticator in axillary node negative breast cancer. Ann Surg Oncol 1995; 2: 32-7
Heuts EM, van der Ent FWC, Hulsewé KWE, von Meyenfeldt MF, Voogd AC. Results of tailored treatment for breast cancer patients with internal mammary lymph node metastases. Breast 2009; 18: 254-8
Carcoforo P, Sortini D, Feggi L, Feo C, Soliani G et al. Clinical and therapeutic importance of sentinel node biopsy of the internal mammary chain in patients with breast cancer: a single-centre study with long-term follow-up. Ann Surg Oncol 2006; 13: 1338-43
Giuliano A, Hunt K, Ballman K, Beitsch P, Whitworth P et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 2011; 305: 569-75
Imasato M, Shimazu K, Tamaki Y, Taguchi T, Tanji Y, Kim S, Noguchi S. Long-term follow-up results of breast cancer patients with sentinel lymph node biopsy using periareolar injection. Am J Surg 2010; 199: 442-6
Langer I, Guller U, Viehl C, Moch H, Wight E et al. Axillary lymph node dissection for sentinel lymph node micrometastases may be safely omitted in early-stage breast cancer patients: long-term outcomes of a prospective study. Ann Surg Oncol 2009; 16: 3366-74
Haid A, Knauer M, Koberle-Wuhrer R, Ammann K, Koller L, Eiter H, Lang A, Wenzel E. Medium-term follow-up data after sentinel node biopsy alone for breast cancer. Eur J Surg Oncol 2006; 32: 1180-5
Palesty J, Foster J, Hurd T, Watroba N, Rezaishiraz H, Edge S. Axillary recurrence in women with a negative sentinel lymph node and no axillary dissection in breast cancer. J Surg Oncol 2006; 93: 129-32
Carcoforo I, Sortini D, Soliani G, Basaglia E, Feggi L, Liboni A. Accuracy and reliability of sentinel node biopsy in patients with breast cancer. Single centre study with long term follow-up. Breast Cancer Res Treat 2006; 95: 111-6
Langer I, Marti W, Guller U, Moch H, Harder F, Oertli D, Zuber M. Axillary recurrence rate in Breast Cancer patients with negative senti- nel lymph node (SLN) or SLN micrometastases. Prospective analysis of 150 patients after SLN biopsy. Ann Surg 2005; 241: 152-8
